Clinical and Biological Characterization of Patients with Low/Intermediate-1 Risk Myelodysplastic Syndrome and Iron Overload

被引:0
|
作者
Ivars, David [1 ]
Collado, Rosa [2 ]
Alguero, Carmen [1 ]
Carmen Tormos, M. [1 ]
Diaz, Laura [1 ]
Luis Garcia-Ghnenez, Jose [3 ]
Arrizabalaga, Beatriz [4 ]
Orero, Mayte [2 ]
Perez, Pedro [2 ]
Sanchez, Magdalena [2 ]
Angeles Ruiz, M. [5 ]
Yaguee, Nuria [5 ]
Sancho-Tello, Reyes [6 ]
Regadera, Ana [7 ]
Tormo, Mar [8 ]
Egea, Mercedes [2 ]
Vidal, Elena [2 ]
Enrique O'Connor, J. [1 ]
Saez, Guillermo T. [1 ]
Carbonell, Felix [2 ]
机构
[1] Univ Valencia, Valencia, Spain
[2] Hosp Gen Univ Valencia, Biomed Diag Ctr, Hematol Serv, Valencia, Spain
[3] Biomed Network Res Ctr Rare Dis, CIBERER, Valencia, Spain
[4] Hosp Cruces, Baracaldo, Spain
[5] Hosp Francesc de Borja, Valencia, Spain
[6] Hosp Arnau Vilanova, Hematol Serv, Valencia, Spain
[7] Hosp Gen Requena, Hematol Serv, Valencia, Spain
[8] Hosp Clin, Valencia, Spain
关键词
D O I
10.1182/blood.V120.21.4956.4956
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
4956
引用
收藏
页数:2
相关论文
共 50 条
  • [41] A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome
    Raza, Azra
    Galili, Naomi
    Smith, Scott E.
    Godwin, John
    Boccia, Ralph V.
    Myint, Han
    Mahadevan, Daruka
    Mulford, Deborah
    Rarick, Mark
    Brown, Gail L.
    Schaar, Dale
    Faderl, Stefan
    Komrokji, Rami S.
    List, Alan F.
    Sekeres, Mikkael
    CANCER, 2012, 118 (08) : 2138 - 2147
  • [42] ANALYSIS OF SHORT-TERM EFFICACY OF LENALIDOMIDE IN PATIENTS WITH INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROME WITHOUT 5Q DELETION
    Yang, Y.
    HAEMATOLOGICA, 2012, 97 : 582 - 582
  • [43] Azacitidine Is Effective in Patients with Low Intermediate-1 Risk Myelodysplastic Syndrome Managed in Community Based Practice: Preliminary Data From the Spanish Compassionate Use Registry
    Garcia, Regina
    de Miguel, Dunia
    Bernal, Maria-Teresa
    Tormo, Mar
    Sanz, Guillermo
    de Paz, Raquel
    Figueredo, Antonio
    Amutio, Maria E.
    Guzman, Jose L.
    BLOOD, 2009, 114 (22) : 1462 - 1462
  • [44] ELTROMBOPAG FOR THE TREATMENT OF THROMBOCYTOPENIA OF LOW AND INTERMEDIATE-1 IPSS RISK MYELODYSPLASTIC SYNDROMES: RESULTS OF A PROSPECTIVE, RANDOMIZED, TRIAL
    Oliva, E.
    Santini, V.
    Zini, G.
    Palumbo, G.
    Poloni, A.
    Cortelezzi, A.
    Rodeghiero, F.
    Voso, M.
    Molteni, A.
    Sanpaolo, G.
    Liberati, A.
    Morabito, F.
    Balleari, E.
    Impera, S.
    Salvi, F.
    Spiriti, M.
    Marino, A.
    Roda, F.
    Alati, C.
    Ronco, F.
    Raimondo, F.
    Leoni, P.
    Alimena, G.
    Fioritoni, G.
    Latagliata, R.
    Nobile, F.
    HAEMATOLOGICA, 2013, 98 : 456 - 456
  • [45] Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome
    Zeidan, Amer M.
    Pullarkat, Vinod A.
    Komrokji, Rami S.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 117 : 57 - 66
  • [46] Eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk myelodysplastic syndromes: Results of a prospective, randomized trial
    Oliva, E. N.
    Santini, V.
    Zini, G.
    Palumbo, G. A.
    Poloni, A.
    Cortelezzi, A.
    Rodeghiero, F.
    Voso, M. T.
    Molteni, A.
    Sanpaolo, G.
    Liberati, M.
    Morabito, F.
    Balleari, E.
    Impera, S.
    Salvi, F.
    Spiriti, M. A. Aloe
    Marino, A.
    Roda, F.
    Alati, C.
    Ronco, F.
    Di Raimondo, F.
    Leoni, P.
    Alimena, G.
    Latagliata, R.
    Nobile, F.
    LEUKEMIA RESEARCH, 2013, 37 : S162 - S162
  • [47] Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial
    Komrokji, Rami S.
    Al Ali, Najla H.
    Padron, Eric
    Cogle, Christopher
    Tinsley, Sara
    Sallman, David
    Lancet, Jeffrey E.
    Lis, Alan F.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (04) : 251 - 254
  • [48] Treatment strategies and issues in low/intermediate-1-risk myelodysplastic syndrome (MDS) patients
    Bowen, DT
    SEMINARS IN ONCOLOGY, 2005, 32 (04) : S16 - S23
  • [49] Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality
    Hironori Harada
    Mitsumasa Watanabe
    Kenshi Suzuki
    Soshi Yanagita
    Takahiro Suzuki
    Yataro Yoshida
    Akiro Kimura
    Mitsuru Tsudo
    Akira Matsuda
    Kaoru Tohyama
    Masafumi Taniwaki
    Kenichi Takeshita
    Masaaki Takatoku
    Keiya Ozawa
    International Journal of Hematology, 2009, 90 : 353 - 360
  • [50] Guidelines on iron chelation therapy in patients with myelodysplastic syndrome and transfusion iron overload
    Gattermann, N.
    LEUKEMIA RESEARCH, 2007, 31 : S15 - S16